Identifying novel small molecule as a preclinical candidate for type II diabetes
- Broad Overview: The design of molecules involved scaffold hopping and bioisosteric modification of known inhibitors of a-glucosidase. Molecular docking experiments confirm the binding interactions of the novel compounds against a-glucosidase. The molecules are generated through new synthetic strategies. Biological studies involved in vitro and in vivo screening, reaction kinetics and tox studies.
- Goals and Objectives: Identifying novel small molecule as a preclinical candidate for type II diabetes
- Collaborators: Dr. Uma Adepally (JNTU, Hyderabad); Dr. Suman Kapur (BITS, Pilani, Hyderabad)
- Students: Ms. Tania Luthra (Ph.D. student) and (Dr. Chandramohan Bathula (graduated 2017)
- Achievement: Identified a target that inhibits a-glucosidase with an IC50 of 50 nM (further studies are ongoing)
- Key publications:
- European Journal of Medicinal Chemistry, 2015, 100, 188
- RSC Advances, 2015, 5, 90374
